Rachel Narozniak, MA

Articles

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 8th 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

December 15th 2020

TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.

The Therapeutic Toolkit for MDS-Associated Anemia Adds Luspatercept

December 2nd 2020

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

METex14+ NSCLC Armamentarium Welcomes First Targeted Therapy

November 19th 2020

The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.

French Study Sheds Light on COVID-19 Stress Among Patients With Cancer

November 13th 2020

Patients on active therapy during the coronavirus disease 2019 pandemic, as well as oncology care providers, have increased levels of perceived and posttraumatic stress, according to preliminary data from the COVIPACT study.

Uncovering TP53 Mutations in MDS, AML Requires NGS

November 12th 2020

TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.

First Nonoperative Option Arrives for Low-Grade UTUC

November 11th 2020

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

October 14th 2020

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

Immunomedics Acquisition Transfers Development of Sacituzumab Govitecan to Gilead Sciences

October 8th 2020

Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.

Emotional AEs Remain a Blindspot in Oncology Care

October 6th 2020

Patients with cancer continue to find their health care providers “more helpful” in managing physical adverse effects resulting from cancer therapy compared with emotional or mental health AEs.

x